GRI Bio to Participate in the Virtual Investor Closing Bell Series
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, has announced its participation in the Virtual Investor Closing Bell Series.
The event will take place on Thursday, December 12th, 2024 at 4:00 PM ET, featuring CEO Marc Hertz, PhD, who will present a corporate overview and business outlook. The session will include a moderated discussion and a live Q&A segment where investors can submit questions.
A live video webcast will be available on the Events page of GRI Bio's website, with a replay accessible for 90 days following the event.
GRI Bio (NASDAQ: GRI), una società biotecnologica focalizzata nello sviluppo di modulatori delle cellule Natural Killer T (NKT) per malattie infiammatorie, fibrotiche e autoimmuni, ha annunciato la sua partecipazione alla Virtual Investor Closing Bell Series.
L'evento si terrà il giovedì 12 dicembre 2024 alle 16:00 ET, con la partecipazione del CEO Marc Hertz, PhD, che presenterà una panoramica aziendale e le prospettive commerciali. La sessione includerà una discussione moderata e un segmento di domande e risposte dal vivo, in cui gli investitori potranno inviare domande.
Una diretta video sarà disponibile sulla pagina Eventi del sito web di GRI Bio, con una registrazione accessibile per 90 giorni dopo l'evento.
GRI Bio (NASDAQ: GRI), una empresa biotecnológica centrada en el desarrollo de moduladores de células Natural Killer T (NKT) para enfermedades inflamatorias, fibróticas y autoinmunes, ha anunciado su participación en la Virtual Investor Closing Bell Series.
El evento se llevará a cabo el jueves 12 de diciembre de 2024 a las 4:00 PM ET, y contará con la presencia del CEO Marc Hertz, PhD, quien presentará una visión general de la empresa y las perspectivas comerciales. La sesión incluirá una discusión moderada y un segmento de preguntas y respuestas en vivo, donde los inversores podrán enviar sus preguntas.
Una transmisión web en vivo estará disponible en la página de Eventos del sitio web de GRI Bio, con una repetición accesible durante 90 días después del evento.
GRI Bio (NASDAQ: GRI)는 염증성, 섬유성 및 자가면역 질환을 위한 자연 살해 T(NKT) 세포 조절제 개발에 집중하는 생명공학 회사로, 가상 투자 클로징 벨 시리즈에 참여한다고 발표했습니다.
이번 행사는 2024년 12월 12일 목요일 오후 4시 ET에 열리며, CEO 마르크 헤르츠 박사가 기업 개요 및 비즈니스 전망을 발표합니다. 세션에는 진행된 토론과 투자자가 질문을 제출할 수 있는 라이브 Q&A 세션이 포함됩니다.
GRI Bio 웹사이트의 이벤트 페이지에서 생중계 비디오가 제공되며, 이벤트 후 90일간 재생이 가능합니다.
GRI Bio (NASDAQ: GRI), une entreprise de biotechnologie axée sur le développement de modulateurs de cellules Natural Killer T (NKT) pour les maladies inflammatoires, fibrotiques et auto-immunes, a annoncé sa participation à la Virtual Investor Closing Bell Series.
L'événement aura lieu le jeudi 12 décembre 2024 à 16h00 ET, avec la participation du PDG Marc Hertz, PhD, qui présentera un aperçu de l'entreprise et des perspectives commerciales. La session comprendra une discussion modérée et un segment de questions-réponses en direct où les investisseurs pourront soumettre leurs questions.
Un webcast vidéo en direct sera disponible sur la page Événements du site web de GRI Bio, avec une rediffusion accessible pendant 90 jours après l'événement.
GRI Bio (NASDAQ: GRI), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Modulatoren der Natural Killer T (NKT) Zellen für entzündliche, fibrotische und autoimmune Erkrankungen spezialisiert hat, hat seine Teilnahme an der Virtuellen Investor Closing Bell Series angekündigt.
Die Veranstaltung findet am Donnerstag, den 12. Dezember 2024 um 16:00 Uhr ET statt und wird vom CEO Marc Hertz, PhD, geleitet, der einen Unternehmensüberblick und die Geschäftsaussichten präsentieren wird. Die Sitzung umfasst eine moderierte Diskussion und einen Live-Q&A-Segment, in dem Investoren Fragen stellen können.
Ein Live-Video-Webcast wird auf der Ereignisse-Seite der GRI Bio-Website verfügbar sein, und eine Aufzeichnung wird für 90 Tage nach der Veranstaltung zugänglich sein.
- None.
- None.
Live webcast on Thursday, December 12th at 4:00 PM ET
LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Thursday, December 12, 2024 at 4:00 PM ET.
As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Events page under the Investors section of the Company’s website (gribio.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
When is GRI Bio's Virtual Investor Closing Bell Series presentation?
What will be discussed during GRI Bio's Virtual Investor presentation?
How can investors access GRI Bio's Virtual Investor presentation?
What is GRI Bio's main focus in biotechnology?
